OpenAI Creates AI That Could Speed Up Medicine Discovery—But It's Not For You

OpenAI just announced a powerful new AI tool that could revolutionize how we discover new medicines—but there's a catch.

The company behind ChatGPT has created an AI model called Rosalind that could dramatically speed up the process of finding new drugs. Currently, it takes pharmaceutical companies (drug makers) 10-15 years and billions of dollars to develop a single new medicine. This AI could potentially cut that time by several years.

How does it work? Rosalind uses artificial intelligence to: • Analyze millions of chemical compounds (the building blocks of medicines) • Predict which ones might work as treatments • Identify potential side effects before expensive testing begins • Suggest the best combinations for specific diseases

The AI is named after Rosalind Franklin, the scientist whose work was crucial to understanding DNA structure.

Here's the catch: Unlike ChatGPT, which anyone can use, Rosalind is only available to large pharmaceutical companies and research institutions. OpenAI says this is because the technology requires specialized knowledge to use safely and effectively.

This exclusivity has sparked debate. While faster drug discovery could mean life-saving medicines reach patients sooner and at lower costs, critics worry that limiting access to big companies could increase the gap between large and small research teams.

The bottom line: This breakthrough shows AI's potential to solve complex scientific problems, but also raises questions about who gets to use these powerful tools. For now, regular users will have to wait and see if the benefits eventually trickle down through cheaper, faster-developed medicines.

This is an AI-generated summary. Read the original article at: https://decrypt.co/364783/openai-gpt-rosalind-drug-discovery-life-sciences-model